KULKARNI SAMARTH (Chief Executive Officer) sold 4.0% of their position (9.80K shares) of CRISPR THERAPEUTICS AG on the open market
Open‑market sale worth $517.3K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 3/12/2026ACC: 0001193125-26-104480
DirectorOfficer· Chief Executive Officer
Since Sep 2018
-9.80K
Net shares
Net seller
$517.3K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
19.25K acquired · 29.05K disposed
Non-Derivative Transactions2
Common Shares
Direct
Shares
+19.25K
Price / share
—
Trade value
—
% of position
8.5%
3/10/2026
226.11K→245.36K
Common Shares
Direct
Shares
−9.80K
Price / share
$52.80
Trade value
$517.33K
% of position
4.0%
3/11/2026
245.36K→235.56K
Total
Net shares
+9.45K
Net value
-$517.33K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Shares Direct | 3/10/2026 | M · Option Exercise | +19.25K | — | — | 8.5% | 226.11K | 245.36K |
| Common Shares Direct | 3/11/2026 | S · Sale | −9.80K | $52.80 | $517.33K | 4.0% | 245.36K | 235.56K |
| Total | +9.45K | -$517.33K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Shares
19.25K shares
Shares
−19.25K
Strike price
Held after
19.25K
Exercisable
—
3/10/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Shares19.25K shares | 3/10/2026 | M · Option Exercise | −19.25K | — | 19.25K |